Nasopharyngeal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Nasopharyngeal Cancer Companies are involved in targeted therapeutics development with respective active and inactive ...
PipelineReview.com17d
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
Martin Olivo, MD, Chief Medical Officer (CMO) of the Company is the former CMO at Systimmune, Inc., and prior VP of Clinical Development at Immunomedics which was acquired by Gilead. Radiance’s ...
manilatimes18d
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
Martin Olivo, MD, Chief Medical Officer (CMO) of the Company is the former CMO at Systimmune, Inc., and prior VP of Clinical Development at Immunomedics which was acquired by Gilead. Radiance's ...
JD Supra18d
Telehealth Transformation: Innovating Mental Health Care Life Sciences Snapshot – Q1 2025
Q4 2024 marked the conclusion of a turnaround year for life sciences venture investment. After two consecutive years of declining activity and macroeconomic uncertainty, the dust has settled, and ...
Business Insider18d
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
Martin Olivo, MD, Chief Medical Officer (CMO) of the Company is the former CMO at Systimmune, Inc., and prior VP of Clinical Development at Immunomedics which was acquired by Gilead. Radiance's ...